Familial Breast Cancer in China

This study is a retrospective descriptive study to collect clinical data (mainly including medical records and follow-up information, etc.) of breast cancer patients with genetic variation who were first diagnosed and treated in a number of hospitals in China during the period from January 1, 2015 to December 31, 2024, and to establish a retrospective cohort of familial hereditary breast cancer. To analyze the clinical features, diagnosis and treatment and survival prognosis of patients with familial hereditary breast cancer. To explore the main factors affecting clinical diagnosis and treatment and survival prognosis of patients

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Breast Carcinoma Breast Diseases Breast Neoplasms Genetic Variation Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–75 year

Sex eligibility

Female

Study type

Observational

Primary location

Cancer Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, 100021, China

Location contact

Xue Wang

CONTACT

[email protected]

86-010-87787242

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Familial inherited breast cancer with genetic variants, including but not limited to mutations in the BRCA1, BRCA2, TP53, and PALB2 genes
The patient had no major organ dysfunction
ECOG score 0-1

Exclusion criteria

There are serious dysfunction of vital organs (heart, liver, kidney)
Patients with other malignancies, except cured non-melanoma skin cancer, cervical carcinoma in situ and other tumors that have been cured for at least 5 years
In other acute infectious disease or chronic infectious disease activity period
A history of uncontrolled seizures, central nervous system disorders, or mental disorders

Treatment and study plan

Genetic variation

Other

To observe and describe the clinical features, diagnosis and treatment plan and survival prognosis of familial hereditary breast cancer in China, and explore the main factors affecting prognosis.

Primary outcomes

Overall survival rate

Time frame: 5-year

Study contacts

Contact information is provided by the study sponsor or research team.

Xue Wang

CONTACT

[email protected]

86-010-87787242

Sponsors and collaborators

Lead sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Other

Registry information

Official study title

A Real-world Study of Familial Hereditary Breast Cancer in China

Important dates

Study start: 2025
Primary completion: 2025
Study completion: 2035
First posted: Feb 18, 2025
Registry last updated: Feb 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting